Abstract 364P
Background
The LIPI index (Lung immune prognostic index) has demonstrated prognostic utility in lung cancer, although it has not been validated in prospective studies. We analyzed the results of this in our sample, as well as the usefulness of other analytical factors not studied.
Methods
Retrospective study of a cohort of 77 patients with advanced NSCLC treated with first-line immunotherapy from January 2021 to June 2024 at the University Hospital of Badajoz. We analyzed the overall survival, as well as stratified by the LIPI index at two different times of treatment (baseline and at 3 months) and by baseline C-reactive protein (CPR) values, using Kaplan-Meier method.
Results
With a mean follow-up of 14.1 months, median overall survival (OS) was 20.7 months (95% CI 16.7–24.7). According to the baseline LIPI index we obtained differences in survival in those subgroups of patients classified as favorable prognosis (22.7 months), intermediate (18.23 months) or poor prognosis (15.5 months) despite not reaching statistical significance (p=0.28). Three months after starting treatment, the difference between those patients stratified as favorable prognosis (25.2 months) and intermediate (24.1 months) practically disappeared. However, it was noticeable with respect to those classified as poor prognosis (10.8 months), p=0.72. Regarding CRP we explored whether there was any relationship as an independent prognostic factor for survival, obtaining statistically significant differences (p=0.047) between those patients with normal CRP values at diagnosis (mSG not reached), elevated values below 100 (19.4 months) and elevated values above 100 (6 months).
Conclusions
Although statistical significance was not reached, the differences obtained in survival, stratified by LIPI, reinforce the prognostic potential of this index as a biomarker of response to immunotherapy. Despite the limitations of our sample, we observed an association between high CRP values at diagnosis and worse survival outcomes. Further prospective studies should be carried out to validate its prognostic role as a biomarker of response to immunotherapy.
Funding
Has not received any funding
Disclosure
All authors have declared no conflicts of interest.